265 related articles for article (PubMed ID: 23559330)
1. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
Sioka C
Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
3. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
5. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
6. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
7. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
8. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
9. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
10.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
11. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
12. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
14. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
15. Comparison of diffusion-weighted MRI and [
Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
[TBL] [Abstract][Full Text] [Related]
16. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.
Cheng G; Chen W; Chamroonrat W; Torigian DA; Zhuang H; Alavi A
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1469-76. PubMed ID: 21505896
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET in children with lymphomas.
Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]